Alnylam Pharmaceuticals

RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA

Healthcare Professionals: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type. Learn more about testing for AHP: https://bit.ly/2RCBrKF

Unlocking the full potential of #RNAiTherapeutics, ensuring that patients at the center of all we do and delivering value to healthcare stakeholders are what drive us to innovate. Our Chief Commercial Officer Tolga Tanguler discusses our approach to patient access in this article where you can also view our latest Patient Access Philosophy Report: https://bit.ly/3WdnzsO #PatientAccess #RNAi #RNAinterference #biotech #biopharma

We're honored to be a #Humankind100 Top 100 company for the 3rd year in a row! The commitment to having a positive impact through the innovative medicines we make and extensive community engagement, while operating ethically and transparently, is deeply personal for our employees and is engrained in every aspect of our business. Learn more about this recognition from Humankind Investments: https://bit.ly/3M7zGRV #CorporateResponsibility #ESG #Sustainability

The sheer scale of people who continue to be displaced due to economic, social, and military conflicts is shocking. Through our Alnylam Challengers social impact program, we support organizations in Spain, the UK, the Netherlands, and Italy, providing critical services to #refugees so they can rebuild their lives with dignity.    I recently visited with our Alnylam Challengers partners Refugee Action, Forward·Inc and Soleterre to hear more about the successes, challenges, and ongoing needs in each country. They described the critical work they do to help refugees prepare for careers in their new homes, from amplifying digital skills to providing language support and much more. They also highlighted how grateful they are for our employees who serve as volunteer mentors and help raise charitable donations to bolster their work. Thanks to my colleagues Marco Fossatelli Fiona McMillan Federica Stucchi Philip Davey Domenico Guajana Christine Regan Lindenboom Brendon Pires Samip Dhakal Seth Levine Sergio Bullón Marta Calomarde for their leadership and support.   To learn more about our Challengers program, read this article written by Phil Davey, Alnyalm Country Manager for the UK & Ireland, and Tim Naor Hilton, Chief Executive, Refugee Action - https://lnkd.in/eRHb4nUf

As a pioneer in RNA-based therapeutics, we relish the opportunity to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us and co-organizers Nature Biotechnology, Ionis Pharmaceuticals, Inc. and UC San Diego School of Medicine at the #RNAbench2bedside conference happening Dec 9-11. Learn more: https://lnkd.in/e5DmnhGA and submit an abstract through Oct 9: https://bit.ly/3WJddzQ #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA

We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: https://bit.ly/3X4wxZL

Happy #RNAday! RNA is truly A-mazing. It’s responsible for many things but primary among them is facilitating protein synthesis - the process by which your body makes new proteins, which are the "workers" in the biochemistry of life. But sometimes, faulty proteins, or too much of a protein, can cause or contribute to disease. Fortunately, a type of RNA can be used to treat disease! RNA interference (RNAi) therapeutics utilize small interfering RNA (siRNA) to prevent the production of these unwanted proteins. Watch this video to learn how. #ScienceCurious to learn even more? Click here: https://bit.ly/3oR8r2l #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA #science

We've reported Q2 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: https://bit.ly/374c75E. Read the Q2 2024 financial results press release: https://bit.ly/4dpnec6 #RNAi #RNAiTherapeutics #siRNA

We'll be sharing 2nd Quarter 2024 financial results this Thursday, 8/1 at 8:30 AM ET, during a LIVE webcast. Register here: https://bit.ly/374c75E and access the replay at the same link later in the day. #RNAi #RNAitherapeutics #siRNA